[Treatment of patients with B-small cell lymphoma using R-CHOP protocol].

Non-Hodgkin's lymphoma is one of the most challenging problems in modern oncology. Creation of drugs inhibiting specifically intracellular signal tracks which being activated in its turn lead to oncogenes hyperexpression and inactivating other genes responsible for suppression of oncogenes, leading eventually to a cell's constant proliferation. This method is a new approach for cancer treatment. Nowadays homogeneous antibodies are widely used against superficial lymphocyte antigens. Rituximab is an anti-CD20 antibody fixed on the surface of malignant cells of most B-small cell lymphomas. In the department of systematic tumors at the institute of oncology of Medical Academy of Sciences a patient with large diffuse B-cell lymphomas had received Rituximab treatment. After the treatment, laboratory data and clinical investigation of the patient showed no signs of the disease. The patient was under observation at the institute of oncology of Medical Academy of Sciences over one year and found clinically, and according to its laboratory data, in a stable remission state.